Friday, 16 October 2026European Markets

AZERION Stock Bullish By 9% So Far On Tuesday

Loading stream...

Today saw a crucial development in the stocks of a major tech company that has been experiencing some lows. Shares of the company, Azerion (AEX-Index: AZRN.AS), rose 9.244% to EUR2.60, providing some relief after the last session's downward trend. Despite this, the overall AEX-Index fell 0.27%, standing at EUR789.90.

About Azerion

Azerion recently closed at EUR2.38, marking an 81.873% drop from its 52-week peak of EUR8.46. Established in 2014 and based in the Netherlands, the company specializes in digital entertainment and media. Azerion offers technology solutions for managing digital advertising inventory while developing social and casual games online.

Azerion's Profitability

If we look into Azerion's profitability, it had trailing twelve-month earnings per share (EPS) of EUR-0.1. Additionally, its return on equity (ROE), an indicator of how profitable the relative shareholder equity was, stood negative at -25.21% for the same period.

Stability and Performance of Azerion's Stocks

Despite the negative profitability, Azerion's current stock value of EUR2.60 is a bit higher than its 50-day moving average of EUR2.44, suggesting a possible investor interest. However, it is significantly below its 200-day moving average of EUR3.51.

Azerion's Operational Performance

The company's EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization), a measure of operational performance, was recorded at 74.03 on September 17. The last reported volume on the trading day was 223,475. This mark represents a 5.35% increase from its average daily volume of 212,117, indicating escalated trading activity.

Outlook

In conclusion, Azerion's shares have been trading at significant lows recently. However, the recent uptick and increased trading activity may be a sign of renewed investor interest in these shares. Nonetheless, potential investors should remain aware of Azerion's negative profitability indicators and market fluctuations before investing.

More news about AZERION (AZRN.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com